HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.

AuthorsAna Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Miguel Teodoro Hernández-Garcia, Silvana Novelli, Reyes Arranz, José Javier Ferreiro, Sabella Bobillo, Santiago Mercadal, Andrea Galeo, Javier López Jiménez, José María Moraleda, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis Palomera, Isidro Jarque, Pilar Martínez-Sánchez, Alejandro Martín, Erika Coria, Armando López-Guillermo, Antonio Salar, Juan José Lahuerta, GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 53 Issue 6 Pg. 780-783 (06 2018) ISSN: 1476-5365 [Electronic] England
PMID29362504 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Rituximab
Topics
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation (adverse effects, methods)
  • Humans
  • Lymphoma, Follicular (complications, pathology, therapy)
  • Male
  • Middle Aged
  • Neoplasms, Second Primary
  • Registries
  • Retrospective Studies
  • Rituximab
  • Survival Analysis
  • Transplantation, Autologous (adverse effects, methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: